SIP/I3 Series - Lana McClements
Topic: Development and translation of novel biomarkers and treatments in cardiovascular disease
About the speaker
Dr McClements is a qualified pharmacist with clinical experience having worked and trained as a clinical pharmacist at the Imperial College Healthcare Trust in London for a number of years. Following her clinical qualifications and experience, she embarked on her research career investigating novel mechanisms of angiogenesis and stem cell signalling. As a PhD student and Research Fellow at Queen’s University Belfast, UK, she has been involved in two projects which were translated into clinic and commercialised. One of these involves a novel anti-cancer agent, ALM201, FKBPL-based anti-angiogenic peptide, which has successfully completed Phase 1 dose-escalation clinical trial for treatment of solid tumours.
As an independent investigator, Dr McClements focused on identifying and developing novel biomarkers and disease mechanisms associated with aberrant angiogenesis, endothelial dysfunction, mesenchymal stem cell activity, oxidative stress, and metabolic dysfunction in diabetes, cardiovascular disease and pre-eclampsia. The methodological approach involves targeted and untargeted discovery through the use of genomics and proteomics. She has been awarded two independent commercialisation grants to develop a novel early biomarker of pre-eclampsia, FKBPL, and to develop a home monitoring platform for pregnant women with diabetes. FKBPL has been patented and is under commercial development through SPARK Sydney. At UTS, Lana is leading the Academic Women in Science Network and is an active member of the Science Equity and Diversity Committee, and the Australia Society for Medical Research.